Ellen Chiniara - 03 Mar 2025 Form 4 Insider Report for Kymera Therapeutics, Inc. (KYMR)

Reporting relationship: Chief Legal Officer
Issuer ticker: KYMR
Reported as of: 03 Mar 2025
Net transaction value: -$68,239
SEC form: 4
Accepted by SEC: 03 Mar 2025, 18:30:08 UTC
Prior SEC filing: 13 Feb 2025
Next SEC filing: 05 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Bruce Jacobs, as Attorney-in-Fact

Key filing fact

Ellen Chiniara filed Form 4 for Kymera Therapeutics, Inc. (KYMR) on 03 Mar 2025.

Key facts

This page summarizes Ellen Chiniara's Form 4 filing for Kymera Therapeutics, Inc. (KYMR).
4 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 03 Mar 2025, 18:30.

Change

Previous filing in this sequence was filed on 13 Feb 2025.
Current net transaction value: -$68,239.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KYMR transaction

Common Stock

Award

Transaction value: $0
Shares: +27,500
Change %: +50%
Price: $0.000000
Shares after: 82,326
Date: 03 Mar 2025
Ownership: Direct
Footnotes: F1

KYMR transaction

Common Stock

Sale

Transaction value: $55,590
Shares: -1,833
Change %: -2.2%
Price: $30.33
Shares after: 80,493
Date: 03 Mar 2025
Ownership: Direct
Footnotes: F2, F3

KYMR transaction

Common Stock

Sale

Transaction value: $12,650
Shares: -408
Change %: -0.51%
Price: $31.00
Shares after: 80,085
Date: 03 Mar 2025
Ownership: Direct
Footnotes: F2, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KYMR transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +55,000
Change %
Price: $0.000000
Shares after: 55,000
Date: 03 Mar 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 55,000
Exercise price: $30.17
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in three equal annual installments following March 3, 2025, subject to the reporting person's continued employment through each vesting date.

Footnote F2

Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person.

Footnote F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.90 to $30.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.90 to $31.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F5

The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 3, 2025, subject to the reporting person's continued employment through each vesting date.